AR053047A1 - 1h-quinazolin-2,4-dionas como ligandos del receptor ampa - Google Patents

1h-quinazolin-2,4-dionas como ligandos del receptor ampa

Info

Publication number
AR053047A1
AR053047A1 ARP060101392A ARP060101392A AR053047A1 AR 053047 A1 AR053047 A1 AR 053047A1 AR P060101392 A ARP060101392 A AR P060101392A AR P060101392 A ARP060101392 A AR P060101392A AR 053047 A1 AR053047 A1 AR 053047A1
Authority
AR
Argentina
Prior art keywords
amino
alkyl
substituents
alkoxy
dialkyl
Prior art date
Application number
ARP060101392A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR053047A1 publication Critical patent/AR053047A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/66—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/18—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups bound to carbon atoms of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/12—Derivatives of isocyanic acid having isocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Dental Preparations (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
ARP060101392A 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas como ligandos del receptor ampa AR053047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0507298.8A GB0507298D0 (en) 2005-04-11 2005-04-11 Organic compounds

Publications (1)

Publication Number Publication Date
AR053047A1 true AR053047A1 (es) 2007-04-18

Family

ID=34610935

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101392A AR053047A1 (es) 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas como ligandos del receptor ampa

Country Status (35)

Country Link
US (4) US7655666B2 (instruction)
EP (4) EP2463278A1 (instruction)
JP (2) JP4898783B2 (instruction)
KR (2) KR100990783B1 (instruction)
CN (2) CN101155789B (instruction)
AR (1) AR053047A1 (instruction)
AU (2) AU2006233639B2 (instruction)
BR (1) BRPI0608617A2 (instruction)
CA (1) CA2601986C (instruction)
CY (2) CY1113573T1 (instruction)
DK (2) DK2468732T3 (instruction)
EC (1) ECSP12007795A (instruction)
ES (2) ES2392542T3 (instruction)
GB (1) GB0507298D0 (instruction)
GT (2) GT200600144AA (instruction)
HR (2) HRP20120867T1 (instruction)
IL (2) IL185544A (instruction)
IN (1) IN2012DN00785A (instruction)
JO (1) JO2770B1 (instruction)
MA (1) MA29411B1 (instruction)
MX (1) MX2007012592A (instruction)
MY (2) MY149070A (instruction)
NO (1) NO20075749L (instruction)
NZ (2) NZ560964A (instruction)
PE (2) PE20091366A1 (instruction)
PL (2) PL2468732T3 (instruction)
PT (2) PT2468732E (instruction)
RU (2) RU2435760C2 (instruction)
SA (2) SA06270089B1 (instruction)
SG (1) SG177182A1 (instruction)
SI (2) SI1871749T1 (instruction)
TN (1) TNSN07383A1 (instruction)
TW (2) TWI385158B (instruction)
WO (1) WO2006108591A1 (instruction)
ZA (2) ZA200807421B (instruction)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200934497A (en) * 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
JP2012506404A (ja) * 2008-10-22 2012-03-15 ノバルティス アーゲー 片頭痛処置用組み合わせ剤
CN102470137A (zh) * 2009-07-23 2012-05-23 诺瓦提斯公司 用于治疗神经元蜡样脂褐质沉积症的1h-喹唑啉-2,4-二酮
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2490691A1 (en) 2009-10-20 2012-08-29 Novartis AG Use of 1h-quinazoline-2,4-diones
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
CN104013587A (zh) * 2009-12-22 2014-09-03 诺华股份有限公司 即释片形式的包含1h-喹唑啉-2,4-二酮ampa受体拮抗剂的制剂及其制备方法
WO2011144666A1 (en) 2010-05-20 2011-11-24 Novartis Ag 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
EP2585070A1 (en) * 2010-06-24 2013-05-01 Novartis AG Use of 1h-quinazoline-2,4-diones
JP5926253B2 (ja) 2010-07-09 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物駆除剤としてのアントラニルアミド誘導体
US9067881B2 (en) 2011-01-24 2015-06-30 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
IN2014DN01791A (instruction) 2011-09-07 2015-05-15 Novartis Ag
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
SG11201605097SA (en) 2013-12-24 2016-07-28 Bristol Myers Squibb Co Tricyclic compounds as anticancer agents
WO2016023826A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Quinazoline-2,4(1h,3h)-dione derivatives as trcp5 modulators for the treatment of neuropsychiatry disorders
KR20210005176A (ko) 2018-05-10 2021-01-13 조에티스 서비시즈 엘엘씨 내부기생충성 뎁시펩타이드

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US535475A (en) 1895-03-12 Governor
GB281309A (en) 1926-11-27 1928-03-29 Inventia Patent Verwert Ges Improvements in or relating to brushing machines having replaceable brush members
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2838519A (en) 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US3310553A (en) 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3637661A (en) 1970-03-04 1972-01-25 Ciba Geigy Corp 10-hydroxy-10 11-dihydro-dibenzazepine derivative
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
WO1988001270A1 (en) * 1986-08-21 1988-02-25 Pfizer Inc. Pyridopyrimidinediones
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5122522A (en) 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
CA2002182C (en) 1989-11-03 2000-06-13 Richard J. Wurtman Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use
IE913473A1 (en) * 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
HU219778B (hu) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
DE4234933A1 (de) 1991-10-31 1993-05-06 Asta Medica Ag, 6000 Frankfurt, De Neue phthalazine, die in 1-stellung eine ether- oder thioether-gruppierung enthalten und verfahren zu deeren herstellung
GB9125485D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
AU4090093A (en) 1992-05-29 1993-12-30 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
US5597922A (en) 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
CA2222713C (en) 1995-07-14 2003-04-22 Andrew John Mcglashan Richards Composition comprising d-threo-methylphenidate and another drug
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5773434A (en) 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
GB9604943D0 (en) 1996-03-08 1996-05-08 Chiroscience Ltd Resolution
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
AU4416197A (en) 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
CZ141399A3 (cs) 1996-10-24 1999-07-14 Novartis Ag Substituované aminoalkanfosfonové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
EP0964860B1 (en) 1997-02-28 2004-04-21 Pfizer Products Inc. Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
CA2308489A1 (en) 1997-10-09 1999-04-22 Emory University Method and devices for transdermal delivery of lithium
GB9721497D0 (en) 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
RU2214405C2 (ru) * 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
US6100401A (en) 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US6162919A (en) 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
JP2000309585A (ja) * 1999-02-26 2000-11-07 Kyorin Pharmaceut Co Ltd ６−置換ヘテロキノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
US7094780B1 (en) 2000-01-24 2006-08-22 Warner Lambert Company Llc 3-aminoquinazolin-2,4-dione antibacterial agents
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US20050037445A1 (en) 2001-06-25 2005-02-17 Poulsen Hans Skovgaard Oncology drug innovation
US20030144234A1 (en) 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US20060264508A1 (en) 2001-10-16 2006-11-23 Stone Richard A Modulation of ocular growth and myopia by gaba drugs
CA2469228A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP4200902B2 (ja) 2002-03-29 2008-12-24 アステラス製薬株式会社 神経膠芽腫治療剤
JP4175846B2 (ja) * 2002-08-08 2008-11-05 独立行政法人科学技術振興機構 Ａｍｐａ型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制
US20040092427A1 (en) 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
JP2006511587A (ja) 2002-12-20 2006-04-06 ミジェニックス コーポレイション アデニンヌクレオチドトランスロカーゼ（ａｎｔ）リガンドならびにそれに関連する組成物および方法
DE60335028D1 (de) 2002-12-23 2010-12-30 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
WO2004067524A1 (en) 2003-01-29 2004-08-12 Pharmagene Laboratories Limited Ep4 receptor antagonists
CN1856310A (zh) 2003-09-23 2006-11-01 默克公司 喹唑啉钾通道抑制剂
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SI1871749T1 (sl) 2012-12-31
PE20061306A1 (es) 2006-12-23
PT2468732E (pt) 2014-11-25
EP2468732B1 (en) 2014-08-20
US20130296332A1 (en) 2013-11-07
DK1871749T3 (da) 2012-11-12
HRP20120867T1 (hr) 2012-11-30
NZ560964A (en) 2011-02-25
RU2007141566A (ru) 2009-05-20
EP2468732A1 (en) 2012-06-27
EP1871749A1 (en) 2008-01-02
EP2463278A1 (en) 2012-06-13
PL2468732T3 (pl) 2015-02-27
MY149070A (en) 2013-07-15
NZ590463A (en) 2012-05-25
SA06270089B1 (ar) 2010-03-20
EP2476671A1 (en) 2012-07-18
TWI440461B (zh) 2014-06-11
JP4898783B2 (ja) 2012-03-21
JP5525500B2 (ja) 2014-06-18
RU2435760C2 (ru) 2011-12-10
AU2011200888A1 (en) 2011-03-24
NO20075749L (no) 2008-01-11
GB0507298D0 (en) 2005-05-18
GT200600144AA (es) 2011-12-13
CA2601986C (en) 2015-03-31
BRPI0608617A2 (pt) 2010-01-19
ES2524316T3 (es) 2014-12-05
TW200716568A (en) 2007-05-01
KR100990783B1 (ko) 2010-10-29
AU2011200888B2 (en) 2012-02-02
AU2006233639A1 (en) 2006-10-19
PT1871749E (pt) 2012-11-14
PL1871749T3 (pl) 2013-01-31
US20100144747A1 (en) 2010-06-10
ZA200807421B (en) 2010-04-28
ZA200707111B (en) 2010-05-26
ES2392542T3 (es) 2012-12-11
US8012988B2 (en) 2011-09-06
GT200600144A (es) 2006-12-18
EP1871749B1 (en) 2012-08-01
WO2006108591A1 (en) 2006-10-19
JO2770B1 (en) 2014-03-15
US7655666B2 (en) 2010-02-02
KR101162827B1 (ko) 2012-07-05
US8513268B2 (en) 2013-08-20
DK2468732T3 (da) 2014-11-10
CN101155789B (zh) 2012-08-29
ECSP12007795A (es) 2013-01-31
TW201304781A (zh) 2013-02-01
US20110294818A1 (en) 2011-12-01
CY1113573T1 (el) 2016-06-22
AU2006233639B2 (en) 2010-12-09
IL220682A0 (en) 2012-08-30
KR20090127944A (ko) 2009-12-14
CY1115767T1 (el) 2017-01-25
SG177182A1 (en) 2012-01-30
TWI385158B (zh) 2013-02-11
MX2007012592A (es) 2007-11-16
HK1113790A1 (en) 2008-10-17
US20080153836A1 (en) 2008-06-26
IL185544A0 (en) 2008-01-06
CN102807531A (zh) 2012-12-05
PE20091366A1 (es) 2009-09-21
CN101155789A (zh) 2008-04-02
KR20070110919A (ko) 2007-11-20
MY142474A (en) 2010-11-30
TNSN07383A1 (en) 2009-03-17
IL220682A (en) 2014-03-31
SI2468732T1 (sl) 2014-12-31
HRP20141116T1 (hr) 2015-01-30
JP2008536839A (ja) 2008-09-11
MA29411B1 (fr) 2008-04-01
IL185544A (en) 2014-03-31
RU2509764C2 (ru) 2014-03-20
SA109300363B1 (ar) 2013-02-06
IN2012DN00785A (instruction) 2015-06-26
RU2011131276A (ru) 2013-02-10
JP2012036203A (ja) 2012-02-23
CA2601986A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
AR053047A1 (es) 1h-quinazolin-2,4-dionas como ligandos del receptor ampa
AR060768A1 (es) Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
AR073138A1 (es) Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol
AR072791A1 (es) DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER.
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
AR082562A1 (es) Derivados de isoxazolina como agentes antiparasitarios
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20080263A1 (es) Compuestos de pirrolo-pirimidina y sus usos
CR11623A (es) Compuestos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
AR060609A1 (es) Compuestos inhibidores de proteinquinasas c-fms.
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
PE20100053A1 (es) Compuestos heterociclicos como inhibidores de la adn girasa
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales
AR070218A1 (es) COMPUESTOS TRICíCLICOS, SUS PROFÁRMACOS, UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA PRODUCCIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR CRF.
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure